SYNTHETIC BIOLOGICS INC | 1,404 Euro | +0,124 +9,69 % | |
| WKN: A1JUA6 ISIN: US87164U1025 Ticker-Symbol: SFYB | Frankfurt | 25.05.12 | 16:51 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 15.05. | Synthetic Biologics Reports First Quarter 2012 Financial Results | 28 | PR Newswire | |
| ANN ARBOR, Mich., May 15, 2012 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses... Mehr lesen zu: Synthetic Biologics Reports First Quarter 2012 Financial Results | ||||
| 14.05. | Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs | 10 | PR Newswire | |
| ANN ARBOR, Mich., May 14, 2012 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses... Mehr lesen zu: Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs | ||||
| 11.05. | Synthetic Biologics, Inc. - 10-K/A, Annual Report | - | SEC Filings | |
| 11.05. | Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman | 31 | PR Newswire | |
| ANN ARBOR, Mich., May 11, 2012 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses... Mehr lesen zu: Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman | ||||
| 30.04. | Synthetic Biologics' Zinc Therapies: Better Preventatives Than Cures? | - | Seeking Alpha | |
| 26.04. | Synthetic Biologics Launches Free Investor Relations Mobile Application | 9 | PR Newswire | |
| ANN ARBOR, Mich., April 26, 2012 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses... Mehr lesen zu: Synthetic Biologics Launches Free Investor Relations Mobile Application | ||||
| 18.04. | Synthetic Biologics Appoints Michael Kaleko, M.D., Ph.D., as Scientific Director | 21 | PR Newswire | |
| ANN ARBOR, Mich., April 18, 2012 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses... Mehr lesen zu: Synthetic Biologics Appoints Michael Kaleko, M.D., Ph.D., as Scientific Director | ||||
| 30.03. | Synthetic Biologics Reports 2011 Year End Financial Results | 53 | PR Newswire | |
| ANN ARBOR, Mich., March 30, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious... Mehr lesen zu: Synthetic Biologics Reports 2011 Year End Financial Results | ||||
| 14.03. | Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta' for Multiple Sclerosis | 43 | PR Newswire | |
| ANN ARBOR, Mich., March 14, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious... Mehr lesen zu: Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta' for Multiple Sclerosis | ||||
| 07.03. | Synthetic Biologics to Present at ROTH Annual Growth Stock Conference | 42 | PR Newswire | |
| ANN ARBOR, Mich., March 7, 2012 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses... Mehr lesen zu: Synthetic Biologics to Present at ROTH Annual Growth Stock Conference | ||||
| 27.02. | S&P Capital IQ Initiates Coverage on Synthetic Biologics, Inc. in Standard & Poor's Factual Stock Reports | 48 | Business Wire | |
| S&P Capital IQ announced today that it has commenced Standard
& Poor's Factual Stock Report coverage on Synthetic Biologics, Inc.
Synthetic Biologics, Inc.... Mehr lesen zu: S&P Capital IQ Initiates Coverage on Synthetic Biologics, Inc. in Standard & Poor's Factual Stock Reports | ||||
| 20.02. | XFRA FRA:New Instruments available on XETRA - 20.02.2012-002 | 133 | Xetra Newsboard | |
| The following instruments on XETRA do have their first trading day 20.02.2012 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 20.02.2012 TrdMod InstCode Exch ISIN Name InstGrp... Mehr lesen zu: XFRA FRA:New Instruments available on XETRA - 20.02.2012-002 | ||||
| 17.02. | XFRA SFYB: AENDERUNG / CHANGE ISIN | 52 | Xetra Newsboard | |
| FUER FOLGENDE INSTRUMENTE WERDEN ISIN, WKN UND KUERZEL GEAENDERT. GUELTIG AB 20.02.2012 FOR THE FOLLOWING INSTRUMENT ISIN, WKN AND SHORT CODE WILL CHANGE. VALID FROM FEBRUARY 20, 2012 EINSTELLUNG ... Mehr lesen zu: XFRA SFYB: AENDERUNG / CHANGE ISIN | ||||
| 16.02. | XFRA SFYB: AUSSETZUNG/SUSPENSION | 42 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT: THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL ADEONA PHARMACEUT. SFYB US00685T1088 BAW/UFN Mehr lesen zu: XFRA SFYB: AUSSETZUNG/SUSPENSION | ||||
| 16.02. | Adeona Becomes Synthetic Biologics, Inc. | 50 | PR Newswire | |
| ANN ARBOR, Mich., Feb. 16, 2012 /PRNewswire/ --Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious... Mehr lesen zu: Adeona Becomes Synthetic Biologics, Inc. | ||||
| 09.02. | Adeona CEO to Present at the Harvard Investors Group Forum | 56 | PR Newswire | |
| ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ --Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious... Mehr lesen zu: Adeona CEO to Present at the Harvard Investors Group Forum | ||||
| 07.02. | Adeona Appoints C. Evan Ballantyne as Chief Financial Officer | 49 | PR Newswire | |
| ANN ARBOR, Mich., Feb. 7, 2012 /PRNewswire/ --Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying... Mehr lesen zu: Adeona Appoints C. Evan Ballantyne as Chief Financial Officer | ||||
| 06.02. | Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus | 54 | PR Newswire | |
| ANN ARBOR, Mich., Feb. 6, 2012 /PRNewswire/ --Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for... Mehr lesen zu: Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus | ||||
| 19.01. | Adeona Announces Initiation of Phase II Clinical Trial of Trimesta' for Cognitive Dysfunction in Multiple Sclerosis | 48 | PR Newswire | |
| ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire/ --Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious... Mehr lesen zu: Adeona Announces Initiation of Phase II Clinical Trial of Trimesta' for Cognitive Dysfunction in Multiple Sclerosis | ||||
| 21.12. | Adeona Pharmaceuticals (AEN) Announces Possible Name Change, Appoints John Monahan Senior VP of R&D | 2 | StreetInsider.com | |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
